Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-Susceptible
Staphylococcus aureus
cefazolin
endocarditis
ertapenem
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
03
02
2022
accepted:
22
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Besides antistaphylococcal beta-lactams and source control, there are limited validated antimicrobial salvage options in patients with prolonged methicillin-susceptible MSSA IE cases treated with ertapenem (ETP) plus cefazolin (CZ) were compared with matched IE cases treated with standard beta-lactam monotherapy. The bactericidal activity of ETP plus CZ was also compared with nafcillin (NAF), CZ, and ETP alone using an in vitro MSSA biofilm model. The median duration of bacteremia experienced by patients (n = 12) while on CZ or NAF was 4 days (range 1-16 days) compared with 1 day (range 1-3 days) for patients (n = 5) treated with ETP + CZ ( Ertapenem reduces CZ concentrations required to eradicate MSSA biofilms to those achievable in vivo by standard dosing, translating into shorter bacteremia duration in patients with MSSA endocarditis. Larger studies are needed to investigate ETP plus CZ therapy in the treatment of biofilm-related MSSA infections such as endocarditis.
Sections du résumé
Background
UNASSIGNED
Besides antistaphylococcal beta-lactams and source control, there are limited validated antimicrobial salvage options in patients with prolonged methicillin-susceptible
Methods
UNASSIGNED
MSSA IE cases treated with ertapenem (ETP) plus cefazolin (CZ) were compared with matched IE cases treated with standard beta-lactam monotherapy. The bactericidal activity of ETP plus CZ was also compared with nafcillin (NAF), CZ, and ETP alone using an in vitro MSSA biofilm model.
Results
UNASSIGNED
The median duration of bacteremia experienced by patients (n = 12) while on CZ or NAF was 4 days (range 1-16 days) compared with 1 day (range 1-3 days) for patients (n = 5) treated with ETP + CZ (
Conclusions
UNASSIGNED
Ertapenem reduces CZ concentrations required to eradicate MSSA biofilms to those achievable in vivo by standard dosing, translating into shorter bacteremia duration in patients with MSSA endocarditis. Larger studies are needed to investigate ETP plus CZ therapy in the treatment of biofilm-related MSSA infections such as endocarditis.
Identifiants
pubmed: 35493130
doi: 10.1093/ofid/ofac159
pii: ofac159
pmc: PMC9045957
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac159Subventions
Organisme : NIAID NIH HHS
ID : K08 AI151253
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145310
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124316
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6609-6618
pubmed: 27572414
Clin Microbiol Rev. 2012 Apr;25(2):362-86
pubmed: 22491776
Infect Immun. 1997 Nov;65(11):4652-60
pubmed: 9353046
PLoS One. 2009 Oct 14;4(10):e7446
pubmed: 19826485
Clin Microbiol Infect. 2014 Dec;20(12):O1075-83
pubmed: 25040215
Clin Infect Dis. 2020 Sep 12;71(6):1413-1418
pubmed: 31773134
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0216621
pubmed: 34978891
J Infect Dis. 1990 Jun;161(6):1170-6
pubmed: 2345297
BMC Microbiol. 2019 Oct 21;19(1):228
pubmed: 31638894
J Infect Dis. 2012 Nov 15;206(10):1604-11
pubmed: 22966128
JAMA. 2014 Oct 1;312(13):1330-41
pubmed: 25268440
Eur J Cardiothorac Surg. 2000 Mar;17(3):228-33
pubmed: 10758380
Arch Intern Med. 2003 Sep 22;163(17):2066-72
pubmed: 14504120
J Infect Dis. 2012 Mar 1;205(5):807-17
pubmed: 22279123
J Card Surg. 2021 Dec;36(12):4786-4788
pubmed: 34599521
J Pediatr Pharmacol Ther. 2020;25(6):547-551
pubmed: 32839659
Antimicrob Agents Chemother. 2011 Jul;55(7):3261-71
pubmed: 21502633
Clin Infect Dis. 2009 May 15;48 Suppl 4:S231-7
pubmed: 19374578